• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

Th17 细胞在慢性淋巴细胞白血病中的作用:是敌是友?

The role of Th17 cells in chronic lymphocytic leukemia: friend or foe?

机构信息

Department of Immunology, H. Lee Moffitt Cancer Center & Research Institute, Tampa, FL.

Department of Molecular Medicine, Morsani College of Medicine, University of South Florida, Tampa, FL.

出版信息

Blood Adv. 2023 Jun 13;7(11):2401-2417. doi: 10.1182/bloodadvances.2022008985.

DOI:10.1182/bloodadvances.2022008985
PMID:36574293
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC10238851/
Abstract

T helper 17 (Th17) cells have a prominent role in autoimmune diseases. In contrast, the nature of these cells in cancer is controversial, with either pro- or antitumorigenic activities depending on various cancer settings. Chronic lymphocytic leukemia (CLL), a B-cell malignancy, is characterized by an imbalance in T-cell immune responses that contributes to disease progression and increased mortality. Many clinical reports indicate an increase in Th17 cells and/or interleukin 17 serum cytokine levels in patients with CLL compared with healthy individuals, which correlates with various prognostic markers and significant changes in the tumor microenvironment. The exact mechanisms by which Th17 cells might contribute to CLL progression remain poorly investigated. In this review, we provide an updated presentation of the clinical information related to the significance of Th17 cells in CLL and their interaction with the complex leukemic microenvironment, including various mediators, immune cells, and nonimmune cells. We also address the available data regarding the effects of CLL-targeted therapies on Th17 cells and the potential of using these cells in adoptive cell therapies. Having a sound understanding of the role played by Th17 cells in CLL is crucial for designing novel therapies that can achieve immune homeostasis and maximize clinical benefits.

摘要

辅助性 T 细胞 17(Th17)细胞在自身免疫性疾病中发挥着重要作用。相比之下,这些细胞在癌症中的性质存在争议,其具有促进或抑制肿瘤发生的活性,具体取决于各种癌症环境。慢性淋巴细胞白血病(CLL)是一种 B 细胞恶性肿瘤,其特征是 T 细胞免疫反应失衡,导致疾病进展和死亡率增加。许多临床报告表明,与健康个体相比,CLL 患者的 Th17 细胞和/或白细胞介素 17 血清细胞因子水平增加,这与各种预后标志物和肿瘤微环境的显著变化相关。Th17 细胞可能促进 CLL 进展的确切机制仍未得到充分研究。在这篇综述中,我们提供了与 Th17 细胞在 CLL 中的意义及其与复杂白血病微环境相互作用相关的临床信息的最新介绍,包括各种介质、免疫细胞和非免疫细胞。我们还讨论了关于 CLL 靶向治疗对 Th17 细胞的影响以及在过继细胞治疗中使用这些细胞的潜力的现有数据。深入了解 Th17 细胞在 CLL 中的作用对于设计能够实现免疫平衡并最大限度地提高临床获益的新型疗法至关重要。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/e3df/10238851/42929f995614/BLOODA_ADV-2022-008985-gr1.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/e3df/10238851/e8087928e9cf/BLOODA_ADV-2022-008985-fx1.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/e3df/10238851/42929f995614/BLOODA_ADV-2022-008985-gr1.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/e3df/10238851/e8087928e9cf/BLOODA_ADV-2022-008985-fx1.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/e3df/10238851/42929f995614/BLOODA_ADV-2022-008985-gr1.jpg

相似文献

1
The role of Th17 cells in chronic lymphocytic leukemia: friend or foe?Th17 细胞在慢性淋巴细胞白血病中的作用:是敌是友?
Blood Adv. 2023 Jun 13;7(11):2401-2417. doi: 10.1182/bloodadvances.2022008985.
2
Identification and characterization of distinct IL-17F expression patterns and signaling pathways in chronic lymphocytic leukemia and normal B lymphocytes.慢性淋巴细胞白血病和正常B淋巴细胞中不同IL-17F表达模式及信号通路的鉴定与表征
Immunol Res. 2015 Dec;63(1-3):216-27. doi: 10.1007/s12026-015-8722-5.
3
The skewed balance between Tregs and Th17 in chronic lymphocytic leukemia.慢性淋巴细胞白血病中调节性T细胞与辅助性T细胞17之间的失衡
Future Oncol. 2015;11(10):1567-82. doi: 10.2217/fon.14.298.
4
Optimization of In Vitro Th17 Polarization for Adoptive Cell Therapy in Chronic Lymphocytic Leukemia.优化体外 Th17 极化用于慢性淋巴细胞白血病的过继细胞治疗。
Int J Mol Sci. 2024 Jun 7;25(12):6324. doi: 10.3390/ijms25126324.
5
Regulatory T-cell and T-helper 17 balance in chronic lymphocytic leukemia progression and autoimmune cytopenias.调节性T细胞与辅助性T细胞17在慢性淋巴细胞白血病进展及自身免疫性血细胞减少症中的平衡
Leuk Lymphoma. 2015;56(8):2424-8. doi: 10.3109/10428194.2014.986479. Epub 2015 Jan 21.
6
Increased IL-10/IL-17 ratio is aggravated along with the prognosis of patients with chronic lymphocytic leukemia.慢性淋巴细胞白血病患者中,白细胞介素-10/白细胞介素-17比值升高随预后恶化而加重。
Int Immunopharmacol. 2016 Nov;40:57-64. doi: 10.1016/j.intimp.2016.07.008. Epub 2016 Aug 29.
7
Disruption of in vivo Chronic Lymphocytic Leukemia Tumor-Microenvironment Interactions by Ibrutinib--Findings from an Investigator-Initiated Phase II Study.依鲁替尼对体内慢性淋巴细胞白血病肿瘤微环境相互作用的破坏——一项研究者发起的II期研究结果
Clin Cancer Res. 2016 Apr 1;22(7):1572-82. doi: 10.1158/1078-0432.CCR-15-1965. Epub 2015 Dec 9.
8
Th17/IL-17A might play a protective role in chronic lymphocytic leukemia immunity.Th17/IL-17A 可能在慢性淋巴细胞白血病免疫中发挥保护作用。
PLoS One. 2013 Nov 1;8(11):e78091. doi: 10.1371/journal.pone.0078091. eCollection 2013.
9
[Proportion and Clinical Significance of γδT17/Th17/Tc17 Cells in Peripheral Blood of Uygur Patients with Chronic Lymphoblastic Leukemia].[维吾尔族慢性淋巴细胞白血病患者外周血中γδT17/Th17/Tc17细胞的比例及临床意义]
Zhongguo Shi Yan Xue Ye Xue Za Zhi. 2024 Feb;32(1):85-89. doi: 10.19746/j.cnki.issn.1009-2137.2024.01.014.
10
The Mithralog EC-7072 Induces Chronic Lymphocytic Leukemia Cell Death by Targeting Tonic B-Cell Receptor Signaling.米托蒽醌 EC-7072 通过靶向 T 细胞受体信号诱导慢性淋巴细胞白血病细胞死亡。
Front Immunol. 2019 Oct 18;10:2455. doi: 10.3389/fimmu.2019.02455. eCollection 2019.

引用本文的文献

1
Impact of mitochondrial metabolism on T-cell dysfunction in chronic lymphocytic leukemia.线粒体代谢对慢性淋巴细胞白血病T细胞功能障碍的影响
Front Cell Dev Biol. 2025 Apr 17;13:1577081. doi: 10.3389/fcell.2025.1577081. eCollection 2025.
2
Leveraging the Immunomodulatory Potential of Ibrutinib for Improved Outcomes of T Cell-Mediated Therapies of B Cell Malignancies: A Narrative Review.利用依鲁替尼的免疫调节潜力改善B细胞恶性肿瘤T细胞介导疗法的疗效:一项叙述性综述
Target Oncol. 2025 Mar;20(2):217-234. doi: 10.1007/s11523-025-01133-9. Epub 2025 Mar 4.
3
Mitigating T-cell mitochondrial dysfunction in CLL to augment CAR T-cell therapy: evaluation in an immunocompetent model.

本文引用的文献

1
Extracellular Vesicle Secretion by Leukemia Cells In Vivo Promotes CLL Progression by Hampering Antitumor T-cell Responses.白血病细胞体内分泌的细胞外囊泡通过阻碍抗肿瘤 T 细胞反应促进 CLL 进展。
Blood Cancer Discov. 2023 Jan 6;4(1):54-77. doi: 10.1158/2643-3230.BCD-22-0029.
2
Activated CLL cells regulate IL-17F-producing Th17 cells in miR155-dependent and outcome-specific manners.活化的 CLL 细胞以 miR155 依赖和预后特异的方式调节产生 IL-17F 的 Th17 细胞。
JCI Insight. 2022 Jun 22;7(12):e158243. doi: 10.1172/jci.insight.158243.
3
Activation and expansion of T-follicular helper cells in chronic lymphocytic leukemia nurselike cell co-cultures.
减轻慢性淋巴细胞白血病中T细胞线粒体功能障碍以增强嵌合抗原受体T细胞疗法:在免疫健全模型中的评估
Blood Adv. 2025 May 27;9(10):2511-2529. doi: 10.1182/bloodadvances.2024014822.
4
The next frontier in immunotherapy: potential and challenges of CAR-macrophages.免疫疗法的下一个前沿领域:嵌合抗原受体巨噬细胞的潜力与挑战。
Exp Hematol Oncol. 2024 Aug 5;13(1):76. doi: 10.1186/s40164-024-00549-9.
5
Optimization of In Vitro Th17 Polarization for Adoptive Cell Therapy in Chronic Lymphocytic Leukemia.优化体外 Th17 极化用于慢性淋巴细胞白血病的过继细胞治疗。
Int J Mol Sci. 2024 Jun 7;25(12):6324. doi: 10.3390/ijms25126324.
6
Rocaglamide promotes infiltration and differentiation of T cells and coordinates with PD-1 inhibitor to overcome checkpoint resistance in multiple tumor models.罗卡酰胺促进 T 细胞浸润和分化,并与 PD-1 抑制剂协同作用,克服多种肿瘤模型中的检查点耐药性。
Cancer Immunol Immunother. 2024 Jun 4;73(8):137. doi: 10.1007/s00262-024-03706-5.
慢性淋巴细胞白血病类成纤维细胞共培养体系中T滤泡辅助细胞的激活与扩增
Leukemia. 2022 May;36(5):1324-1335. doi: 10.1038/s41375-022-01519-y. Epub 2022 Feb 11.
4
Cancer statistics, 2022.癌症统计数据,2022 年。
CA Cancer J Clin. 2022 Jan;72(1):7-33. doi: 10.3322/caac.21708. Epub 2022 Jan 12.
5
CAR T-Cell Therapy for Large B-Cell Lymphoma - Who, When, and How?用于大B细胞淋巴瘤的嵌合抗原受体T细胞疗法——适用人群、时机及方式?
N Engl J Med. 2022 Feb 17;386(7):692-696. doi: 10.1056/NEJMe2118899. Epub 2021 Dec 14.
6
Stem-like intestinal Th17 cells give rise to pathogenic effector T cells during autoimmunity.在自身免疫中,类干细胞样的肠道 Th17 细胞可分化为致病性效应 T 细胞。
Cell. 2021 Dec 22;184(26):6281-6298.e23. doi: 10.1016/j.cell.2021.11.018. Epub 2021 Dec 6.
7
A T cell inflammatory phenotype is associated with autoimmune toxicity of the PI3K inhibitor duvelisib in chronic lymphocytic leukemia.T 细胞炎症表型与 PI3K 抑制剂 duvelisib 在慢性淋巴细胞白血病中的自身免疫毒性有关。
Leukemia. 2022 Mar;36(3):723-732. doi: 10.1038/s41375-021-01441-9. Epub 2021 Nov 6.
8
Chronic lymphocytic leukemia: 2022 update on diagnostic and therapeutic procedures.慢性淋巴细胞白血病:诊断与治疗程序的 2022 年更新。
Am J Hematol. 2021 Dec 1;96(12):1679-1705. doi: 10.1002/ajh.26367.
9
Autoimmune cytopenia and CLL ride together.自身免疫性血细胞减少症与慢性淋巴细胞白血病相伴出现。
Blood. 2021 Jun 24;137(25):3464-3465. doi: 10.1182/blood.2021010944.
10
Activated Galectin-9/Tim3 promotes Treg and suppresses Th1 effector function in chronic lymphocytic leukemia.激活的半乳糖凝集素-9/Tim3 在慢性淋巴细胞白血病中促进 Treg 并抑制 Th1 效应功能。
FASEB J. 2021 Jul;35(7):e21556. doi: 10.1096/fj.202100013R.